Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19.
作者信息
Funck-Brentano Christian, Nguyen Lee S, Salem Joe-Elie
机构信息
AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France; INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France.
AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France; INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France.
出版信息
Lancet. 2020 Jul 18;396(10245):e2-e3. doi: 10.1016/S0140-6736(20)31528-2. Epub 2020 Jul 9.
Abstract
摘要
相似文献
1
Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19.撤稿与重新发表：羟氯喹在2019冠状病毒病中的心脏毒性
Lancet. 2020 Jul 18;396(10245):e2-e3. doi: 10.1016/S0140-6736(20)31528-2. Epub 2020 Jul 9.
2
Retraction and republication: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.撤稿与重新发表：出院的 COVID-19 患者6个月后的情况：一项队列研究。
Lancet. 2023 Jun 17;401(10393):2025. doi: 10.1016/S0140-6736(23)01175-3. Epub 2023 Jun 9.
3
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.氯喹和羟氯喹在治疗性使用或过量使用后的毒性。
Clin Toxicol (Phila). 2021 Jan;59(1):12-23. doi: 10.1080/15563650.2020.1817479. Epub 2020 Sep 22.
4
An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19.关于新冠病毒疾病（COVID-19）患者使用羟氯喹啉或氯喹啉（无论是否联合阿奇霉素）相关临床疗效及不良心脏事件的伞状综述
Anesth Pain Med. 2021 Aug 15;11(4):e115827. doi: 10.5812/aapm.115827. eCollection 2021 Aug.
5
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.COVID-19 药物治疗的心脏安全性：综述及建议监测方案。
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221. doi: 10.1177/2048872620922784. Epub 2020 May 6.
6
Hydroxychloroquine and COVID-19 - A narrative review.羟氯喹与2019冠状病毒病——一篇叙述性综述。
Indian J Tuberc. 2020 Dec;67(4S):S147-S154. doi: 10.1016/j.ijtb.2020.06.004. Epub 2020 Jul 3.
7
Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted.为何导致羟氯喹在新冠疫情中广泛使用的那篇文章应被撤回。
Therapie. 2023 Jul-Aug;78(4):437-440. doi: 10.1016/j.therap.2023.06.001. Epub 2023 Jun 2.
8
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data.羟氯喹在 COVID-19 患者中的超适应证治疗的安全性概况：基于 EudraVigilance 数据的描述性研究。
Fundam Clin Pharmacol. 2022 Dec;36(6):1099-1105. doi: 10.1111/fcp.12797. Epub 2022 May 13.
9
Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.羟氯喹故意过量服用并用大剂量地西泮治疗：COVID-19 大流行中的一个日益令人关注的问题。
J Med Toxicol. 2020 Jul;16(3):314-320. doi: 10.1007/s13181-020-00790-8. Epub 2020 Jun 8.
10
"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.羟氯喹、阿奇霉素、洛匹那韦-利托那韦和氯喹在 COVID-19 中的“超适应证”使用：法国药物警戒中心网络对心脏不良药物反应的调查。
Therapie. 2020 Jul-Aug;75(4):371-379. doi: 10.1016/j.therap.2020.05.002. Epub 2020 May 7.
引用本文的文献
1
The role of evidence-based medicine in the media: misinformation and the COVID-19 lesson.循证医学在媒体中的作用：错误信息与新冠疫情的教训
Eur Respir Rev. 2025 Jun 25;34(176). doi: 10.1183/16000617.0278-2024. Print 2025 May.
2
Biased, wrong and counterfeited evidences published during the COVID-19 pandemic, a systematic review of retracted COVID-19 papers.新冠疫情期间发表的有偏见、错误和伪造的证据：对撤回的新冠论文的系统评价
Qual Quant. 2022 Nov 29:1-33. doi: 10.1007/s11135-022-01587-3.
3
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.系统性红斑狼疮患者感染 SARS-CoV-2 疫苗的安全性和耐受性：COVAD 研究结果。
Rheumatology (Oxford). 2023 Jul 5;62(7):2453-2463. doi: 10.1093/rheumatology/keac661.
4
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.氯喹和阿奇霉素在健康志愿者中的药代动力学和心电图评估。
Clin Pharmacol Ther. 2022 Oct;112(4):824-835. doi: 10.1002/cpt.2665. Epub 2022 Jun 22.
5
Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic.羟氯喹在 SARS-CoV2 大流行前后的不良事件谱的对比研究。
Therapie. 2022 May-Jun;77(3):301-307. doi: 10.1016/j.therap.2021.12.015. Epub 2021 Dec 28.
6
Navigating ethical challenges of conducting randomized clinical trials on COVID-19.应对新冠病毒随机临床试验中的伦理挑战。
Philos Ethics Humanit Med. 2022 Jan 28;17(1):2. doi: 10.1186/s13010-022-00115-3.
7
COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-κB Pathway.COVID-19：非洲悖论的机械模型支持 NF-κB 通路的核心作用。
Viruses. 2021 Sep 21;13(9):1887. doi: 10.3390/v13091887.
8
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.羟氯喹和阿奇霉素对住院治疗的 COVID-19 肺炎患者无效：一项回顾性研究。
PLoS One. 2021 Jun 9;16(6):e0252388. doi: 10.1371/journal.pone.0252388. eCollection 2021.
9
Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.类黄酮作为对抗 SARS-CoV-2 细胞因子风暴的潜在植物疗法。
Phytother Res. 2021 Aug;35(8):4258-4283. doi: 10.1002/ptr.7092. Epub 2021 Mar 30.
10
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.SARS-CoV-2：感染引起的免疫反应和疫苗及治疗的发展。
Front Immunol. 2020 Dec 11;11:569760. doi: 10.3389/fimmu.2020.569760. eCollection 2020.
本文引用的文献
1
Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing.重庆 COVID-19 患者住院期间入院时收集的变量与向重症病例进展的相关性。
J Med Virol. 2020 Nov;92(11):2616-2622. doi: 10.1002/jmv.26082. Epub 2020 Jun 9.
2
Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?氯喹或羟氯喹用于治疗新型冠状病毒肺炎：为何它们可能具有危险性？
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31174-0.
3
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回：羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册分析
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
4
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.羟氯喹啉和阿奇霉素相关的心血管毒性：世界卫生组织药物警戒数据库分析
Circulation. 2020 Jul 21;142(3):303-305. doi: 10.1161/CIRCULATIONAHA.120.048238. Epub 2020 May 22.
5
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.纽约州 COVID-19 患者住院死亡率与羟氯喹或阿奇霉素治疗的关联。
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
6
Chloroquine-induced QTc prolongation in COVID-19 patients.新冠患者中氯喹引起的QTc间期延长
Neth Heart J. 2020 Jul;28(7-8):406-409. doi: 10.1007/s12471-020-01429-7.
7
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.对社论《心血管疾病患者的COVID-19》的回应：使用羟氯喹或氯喹及阿奇霉素治疗COVID-19：尖端扭转型室速的潜在风险。
Arch Cardiovasc Dis. 2020 May;113(5):367-368. doi: 10.1016/j.acvd.2020.04.001. Epub 2020 Apr 15.
8
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
9
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.德国有症状的药物诱导长 QT 综合征和尖端扭转型室性心动过速的流行病学。
Europace. 2014 Jan;16(1):101-8. doi: 10.1093/europace/eut214. Epub 2013 Jul 5.
10
Cardiotoxicity of antimalarial drugs.抗疟药物的心脏毒性。
Lancet Infect Dis. 2007 Aug;7(8):549-58. doi: 10.1016/S1473-3099(07)70187-1.
Zotero 插件